Has science found a way to get villainous clumps of protein to cure instead of kill? Possibly, say European researchers whose early-stage findings might spur a new class of cancer therapeutics.

The team created an artificial protein containing amyloids — sequences that, under the right conditions, cause proteins to clump together. Those clumps are seen in the brains of people with neurodegenerative diseases like Alzheimer’s and Parkinson’s. The researchers wanted to know: Could they create synthetic versions of those tangles and use them to halt the flow of blood to a tumor — and thus stop the cancer in its tracks?

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy